Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Adjuvant and neoadjuvant systemic therapy of breast carcinoma].
Schmid P, Possinger K. Schmid P, et al. Among authors: possinger k. Internist (Berl). 2002 Mar;43(3):341-4, 347-53. doi: 10.1007/s00108-001-0523-3. Internist (Berl). 2002. PMID: 11963719 Review. German. No abstract available.
[High-dose chemotherapy in breast cancer].
Schmid P, Possinger K. Schmid P, et al. Among authors: possinger k. Med Klin (Munich). 2002 Nov 15;97(11):677-86. doi: 10.1007/s00063-002-1211-3. Med Klin (Munich). 2002. PMID: 12434276 Review. German.
Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K; TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Schmid P, et al. Among authors: possinger k. Anticancer Res. 2002 Jul-Aug;22(4):2325-32. Anticancer Res. 2002. PMID: 12174922 Clinical Trial.
Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients.
Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K; Takeda Adjuvant Breast Cancer Study with Leuprorelin Study Group. Lüftner D, et al. Among authors: possinger k. Breast Cancer Res Treat. 2003 Aug;80(3):245-55. doi: 10.1023/a:1024911625339. Breast Cancer Res Treat. 2003. PMID: 14503797 Clinical Trial.
253 results